Results 111 to 120 of about 13,816 (168)

Once-Weekly Liposomal Amphotericin B Use for Maintenance and Consolidation Phase Treatment of Cryptococcal Meningitis in Patients With AIDS. [PDF]

Cureus
Belinschi V, Iheagwara C, Muhanna A.
europepmc   +1 more source

A Real-World Data Observational Analysis of the Impact of Liposomal Amphotericin B on Renal Function Using Machine Learning in Critically Ill Patients. [PDF]

Antibiotics (Basel)
Sacanella I, Esteve-Pitarch E, Guevara-Chaux J, Berrueta J, García-Martínez A, Gómez J, Casarino C, Alés F, Canadell L, Martín-Loeches I, Grau S, Candel FJ, Bodí M, Rodríguez A.   +13 more
europepmc   +1 more source

Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit. [PDF]

Infection
Fumarola B, Signorini L, Lorenzotti S, Lanza P, Saccani B, Van Hauwermeiren E, Mulè A, Piva S, Rota M, Zuccalà F, Rasulo FA, Filippini M, Bertazzoli A, Del Fabro G, Matteelli A.   +14 more
europepmc   +1 more source

Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris: Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model. [PDF]

J Infect Dis
Beredaki MI, Sanidopoulos I, Pournaras S, Meletiadis J.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Liposomal amphotericin B, AmBisome

Journal of Infection, 1994
The unilamellar liposomal formulation of amphotericin B, AmBisome, is composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol and cholesterol. Early studies of its efficacy in an open design showed that remissions could be induced in candidosis and aspergillosis and that doses of up to 5 mg/kg could be used.
openaire   +2 more sources

Amphotericin B/amphotericin B liposomal

Reactions Weekly, 2023
openaire   +2 more sources

Amphotericin-B-liposomal

Reactions Weekly, 2023
  +5 more sources